Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey

JoAnn V. Pinkerton, MD,1 and Ginger D. Constantine, MD2

Abstract

Objective: From a survey of compounding pharmacist's, specific questions regarding compounded menopausal hormone therapy were used to estimate compounded hormone therapy (CHT) prescribing in the United States.

Methods: A national online survey was conducted by Rose Research—a market research company consisting of 12,250 US pharmacists from independent community pharmacies (ICPs) and compounding pharmacies (CPs). Pharmacists who completed the survey and met the prespecified criteria were eligible. Data from the survey were extrapolated to estimate overall CHT prescription volume and annual costs of CHT prescriptions for the United States based upon industry data from the National Community Pharmacists Association and IBISWorld.

Results: Surveys were completed by 483 pharmacies, including 365 ICPs and 118 CPs. On the basis of the survey responses and extrapolated industry data, an estimated 26 to 33 million CHT prescriptions were filled annually, with total sales estimated at $1.3 to $1.6 billion. CPs (vs ICPs) accounted for a higher proportion of CHT prescriptions. More than half of the ICPs (52%) and CPs (75%) expected continued compounding business growth, with most predicting 5% to 25% growth within 2 years, despite the potential effect of restrictive legislation regarding compounding.

Conclusions: On the basis of extrapolated data from numbers of prescriptions reported by pharmacists participating in the survey, the volume of CHT seems to approach that of Food and Drug Administration (FDA)-approved menopausal hormone therapy, and growth in the CHT market is expected. Thus, physicians should educate themselves and the women consulting them about the differences between the FDA-approved and the less-tested CHT formulations. More research on the efficacy, safety, and consistency of non-FDA–approved CHT is needed.

Key Words: Compounded hormone therapy – Compounding pharmacies – Estrogen therapy – Menopause – Progesterone.
Compounded hormone therapy formulations may have unique risks and may contain non-FDA-approved hormones (eg, estril) or may have undesirable additives or preservatives. They are not monitored by the FDA for purity or dose standardization, and they are not required to carry a package insert (PI); thus they do not include potential warnings/contraindications as is required for FDA-approved MHT. The products have not undergone FDA-approved rigorous studies evaluating efficacy or potential risk, and no pharmacokinetic data are available for CHT formulations. Recent consumer online survey data indicate that 86% of consumers were unsure or unaware that these formulations are not FDA-approved, whereas many websites for CHT are claiming better safety than for FDA-approved products. Purported individualization of therapy is frequently recommended by compounders via salivary estradiol and progesterone levels remains unproven. In 2008, the FDA censured seven pharmacies because of unsubstantiated product claims.

The majority of pharmacies and their professional organizations are dedicated to providing high-quality products. Compounding pharmacies now have the option of being accredited by the Pharmacy Compounding Accreditation Board (PCAB). The US Pharmacopeial Convention (USP) has developed standards for compounding to “help compounding practitioners adhere to widely acknowledged, scientifically sound procedures and practices, and facilitate the delivery of consistent and good-quality prepared medicines to people who are need of them.”

Given that the use and incidence of CHT prescribing seem to have increased, and that the population is aging, more research on actual prescribing and use of compounded products is needed. To date, however, few reliable data are available on the extent of prescribing of CHT by US pharmacies and expected future trends. Previously published consumer surveys by Pinkerton and Santoro suggest high-volume use of CHT.

Using data from a large internet survey of US pharmacies conducted by Rose Research—a market research firm—and additional data from the National Community Pharmacists Association (NCPA) and IBISWorld, we have estimated the extent of CHT prescribing and overall annual costs.

### METHODS

#### Survey design

Rose Research conducted a benchmarking internet survey of pharmacists who provide compounding services in the United States. The survey was conducted on behalf of the International Journal of Pharmaceutical Compounding and inThought Research, LLC—a market research company, and was sponsored by TherapeuticsMD—a pharmaceutical company focused on research and development of products exclusively for women’s health. Eligible participants were recruited from the healthcare populations of two online sample panel providers—Toluna and ResearchNow.

### Table 1. Glossary of abbreviations

| Abbreviation | Definition |
|--------------|------------|
| AACE         | American Association of Clinical Endocrinologists |
| ACCP         | American College of Clinical Pharmacy |
| ACOG         | American Congress of Obstetricians and Gynecologists |
| AMS          | Australian Menopause Society |
| ASRM         | American Society for Reproductive Medicine |
| BHRT         | Bioidentical hormone replacement therapy |
| CHT          | Compounded hormone therapy |
| CP           | Compounding pharmacies |
| FDA          | US Food and Drug Administration |
| GSM          | Genitourinary syndrome of menopause |
| HT           | Hormone therapy |
| ICP          | Independent community pharmacies |
| MHT          | Menopausal hormone therapy |
| NA           | Not applicable |
| NAMS         | North American Menopause Society |
| NCPA         | National Community Pharmacists Association |
| NHANES       | National Health and Nutrition Examination Survey |
| PCAB         | Pharmacy Compounding Accreditation Board |
| Rx           | Prescriptions |
| USP          | United States Pharmacopoeia |
| VVA          | Vulvar and vaginal atrophy |
| WHI          | Women’s Health Initiative |

Prescriptions written immediately after publication of the WHI findings, with one estimate indicating a 68% decline in overall MHT prescriptions between 2001 and 2008, and another citing up to an 85% decline for estrogen–progestins between 2001 and 2005. The decline of Food and Drug Administration (FDA)-approved MHT has slowly abated, with a very slight upturn between 2005 and 2010. Componded hormone therapy (CHT), also referred to as “bioidentical hormone replacement therapy” (BHRT), is a marketing term that is not recognized by the FDA. After the WHI reports in 2002, and the 2001 US Supreme Court ruling allowing pharmacies to market compounded products that were unregulated by the FDA, the use of CHT became more prominent, whereas the use of FDA-approved MHT declined. Many women consider CHT options to be more “natural” and safer because of unsubstantiated safety and efficacy claims in the media, internet, and from celebrities promoting them as a superior alternative to approved MHT.

Prescription data for FDA-approved MHT are tracked and can be quantified, whereas compounded products are not FDA-approved and are thus not tracked. Therefore, surveys and market research studies have been performed in an attempt to understand the prescription numbers, use, and reasons for continued compounding. In a survey of 184 postmenopausal women presenting for consultation at the Mayo Clinic, Iftikhar et al found that 20% reported ever-use and 14% reported current use of CHT. Pinkerton and Santoro reported data from an online survey in 2013 and 2014 among more than 2,800 women aged 40 to 60 years, and extrapolating data from these surveys estimated that 1 to 2.5 million US women use CHT annually, with 21 to 39 million annual CHT prescriptions representing 28% to 68% of overall MHT prescribing, totaling $1 to $2 billion in spending.
Sample and inclusion criteria
A representative sample of pharmacists (n = 12,250) was invited to participate in the survey between October and November 2014. This was out of a total estimated sample size for independent community pharmacies (ICPs) of approximately 3.1 pharmacists per each of the 23,000 ICPs, or 71,300 compounding pharmacists; similar total estimated sample size for community pharmacies (CPs) is not available. Large chain pharmacies were not included because they generally do not perform compounding of hormonal agents. Pharmacists qualified for participation if they met the following criteria: pharmacy is in the United States; pharmacy is either an independent community pharmacy (ICP) defined as a small chain with <50 stores) or an independent compounding pharmacy (CP—defined as a retail pharmacy not directly affiliated with any chain of pharmacies or not owned or operated by a publicly traded company); pharmacist has knowledge of the pharmacy’s annual revenue and prescription volume composition for both compounded and noncompounded prescriptions for all pharmacy locations; and the prescription volume from nonsterile-compounded prescriptions represents at least 1% of the total prescription revenue and volume. Participants were advised of the goals of the survey and that the composite results would be published. Individual participants were not identified; therefore they were not asked to provide written informed consent. Multiple pharmacists per pharmacy could potentially have responded to the survey, but due to the confidential nature of the survey, the number of pharmacists who responded per pharmacy was not quantified. Participation was voluntary and participants were assured that their answers and identifying information would remain confidential. Respondents received an equivalent of up to approximately $17 to $35 in cash or merchandise for their time utilized to complete the survey.

Survey instrument
The survey was intended to gather data on compounding practices and expected future trends in various classes of pharmaceuticals, including analgesic, adult antibiotic, MHT/CHT, pediatric, veterinary, and others, and also details about business practices (eg, consumer categories, services other than prescribing, and other aspects of the business model). The overall survey goals were to provide insight into the role that compounding plays in the marketplace for both ICPs and CPs; quantify the nature of business for sterile compounded medications and nonsterile compounded medications for pharmacies in the United States; analyze the types of medicines compounded for what purposes; analyze the importance of compounding and other services in the business model; and identify past trends and future expectations for ICPs and CPs with regard to how growth, acquisitions, and regulation affect their business model.

Thirty-one questions about sterile and nonsterile compounding were included in the survey. Specific questions were included in the survey to ask about the number, volume, and overall costs of prescriptions for CHT sold by US pharmacies; specific quantities and types of CHT provided; and reported past trends and estimated future growth of the CHT industry. Six questions specific to compounded menopausal hormone therapies (Appendix A, Supplemental Digital Content 1, http://links.lww.com/MENO/A141), including CHT prescription numbers and percentage of total volume, percentages of various types of CHT, and the likelihood of change in CHT prescribing over the next 2 years, formed the basis of our analysis. Questions about testosterone alone were not included in this study as testosterone alone is not used for treatment of vasomotor symptoms.

Data analyses
Nationwide volume and sales of CHT were estimated utilizing two different methods to assure consistency of results. In the first method, pharmacists were asked to quantify and report the number of “compounded menopausal hormone therapies” that they dispensed per month. These data were then paired with data from the NCPA (2013) and IBISWorld (Industry Data, 2014) that estimate overall numbers. The number of CHT prescriptions written annually was calculated based upon the estimate of CHT dispensed by the individual compounding pharmacists who participated in the survey and multiplied by the total number of ICPs and CPs. The average out-of-pocket monthly cost to the consumer of $49 per prescription previously reported by completers of the Rose consumer survey was used to estimate the annual nationwide CHT spent. The second method asked the pharmacists to indicate the volume of each individual type of CHT dispensed per month (eg, estradiol, progesterone). The individual compounded hormones were used in conjunction with the industry data (NCPA, 2013 and IBISWorld [Industry Data, 2014]) to reach an estimate of nationwide CHT volume. The $49 per month cost per prescription was applied as in the first method.

RESULTS
Response rates and pharmacy characteristics
Of the 12,250 candidate pharmacists, 2,902 (24%) answered the online survey screening questions, and 904 of these were eligible for the survey based on meeting inclusion criteria. Although we have no way of confirming number of respondents per pharmacy, our responses indicated that 685 pharmacies from this sample performed compounding services (76%). Surveys were completed by 483 of these pharmacies (71%), including 365 ICPs and 118 CPs (Fig. 1). Characteristics of the respondents are listed in Appendix B (Supplemental Digital Content 2, http://links.lww.com/MENO/A142). No statistical comparisons were made between the ICP and CP groups as demographic data were not requested of the survey participants. Also, given the confidential nature of the survey, we do not know if more than one pharmacist from each pharmacy participated. Geographic distribution of the pharmacies (Appendix C, Supplemental Digital Content 3, http://links.lww.com/MENO/A143) shows widespread representation across the country.

Menopause, Vol. 23, No. 4, 2016 361
CHT prescribing volume and costs estimated using overall prescription volume

Survey responses for mean and median number of prescriptions filled per week are indicated in Table 2. Median values for total annual prescriptions were extrapolated from weekly data, amounting to 65,520 for ICPs and 61,100 for CPs (Table 2, Fig. 2A), and served as the basis of all subsequent calculations. ICPs reported that 8.6% of overall prescriptions (mean) were for nonsterile compounded products, and out of this number, 16.1% (mean) were CHT; respective values for CPs were 36.0% (mean) and 25.7% (mean; Fig. 2A). Data from NCPA estimate that there are at least 23,000 ICPs in the United States and 63% of these offer compounding services, which amounts to approximately 14,490 compounding ICPs (Fig. 2A). Data from IBISWorld cite 3,556 CPs in the United States in 2013, so a conservative estimate of 3,500 was used in calculations to estimate total number of CHT prescriptions per year and the total cost of those prescriptions (Fig. 2A). Therefore, based on survey responses and extrapolated industry data, an estimated 33 million CHT prescriptions are filled annually by both ICPs and CPs combined (Fig. 2A).

Calculations of total costs used the estimate of $49 out-of-pocket per prescription. Multiplying the total volume per year by this price yields an estimated $1.61 billion in spending for CHT each year (Fig. 2A).

CHT prescribing volume and costs estimated using volume of individual types of prescriptions

Estimates of the number of CHT prescriptions per year and the costs of those prescriptions were also extrapolated from the volumes of individual types of CHT provided (Table 2, Fig. 2B). In the survey, ICPs and CPs reported the number of prescriptions filled per month for each type of CHT they provide (Table 2). Most common was progesterone/progestin only, followed by estrogen and progesterone/progestin combinations, and 17β-estradiol/estrogen combinations. The predominant route of administration was transdermal gel or lotion (reported by 46% of ICPs and 37% of CPs), followed by oral (24% and 27%) and vaginal (22% and 17%).

The sum of all prescriptions reported per CHT type per pharmacy in Table 2 is an estimated 76.3 total CHT prescriptions filled per month per pharmacy for ICPs and 296.3 prescriptions per month per pharmacy for CPs. When annual volume was estimated using these numbers and the same industry data as in Figure 2A, the calculations showed total combined CHT prescriptions of 26 million per year (Fig. 2B). Cost calculation based on the unit cost of $49 yields an estimated total cost of $1.26 billion in spending (Fig. 2B).

Comparison of ICPs and CPs

Surveyed CPs (vs ICPs) accounted for a numerically higher proportion of CHT prescriptions, whether expressed in relation to overall annual prescribing (26% vs 16%; Fig. 2A) or sum of annual prescriptions for all individual CHT products (3,555 vs 915; Fig. 2B). CPs (vs ICPs) also

![FIG. 1. Flow of participants into the study. CPs, compounding pharmacies; ICPs, independent community pharmacies. “Incomplete knowledge about their pharmacies compounding volume and revenue.](image)

**TABLE 2.** Total prescriptions filled per week (extrapolated per year) per pharmacy and number of monthly prescriptions by specific CHT type from the pharmacy survey

|                      | Independent community pharmacy (n = 365) | Compounding pharmacy (n = 118) |
|----------------------|----------------------------------------|--------------------------------|
| Total prescriptions  | Weekly                                 | Yearly                          | Weekly                                 | Yearly                          |
| Mean                 | 2,081                                  | 108,212                         | 1,510                                  | 78,520                          |
| Median               | 1,260                                  | 65,520                          | 1,175                                  | 61,100                          |
| Monthly prescriptions, mean (±SE) |                                      |                                |                                        |                                |
| 17β-estradiol/estrogen only | 11.44 (±2.19)                          | 50.44 (±16.61)                  |                                          |                                |
| Progesterone/progestin only | 21.28 (±3.78)                          | 80.34 (±14.81)                  |                                          |                                |
| Estrogen and progesterone/progestin combination | 19.45 (±3.59)                          | 76.59 (±21.35)                  |                                          |                                |
| Estrogen and testosterone combination | 12.2 (±2.45)                           | 45.28 (±9.63)                   |                                          |                                |
| Testosterone, estrogen, and progesterone/progestin combination | 11.89 (±2.42)                          | 43.5 (±10.62)                   |                                          |                                |

CHT, compounded hormone therapy; SE, standard error.

**a**ICPs: 8.6% (mean) of overall prescriptions are for non-sterile compounded products; 16.1% of this number was CHT.

**b**Calculated per year based on weekly report of CHT.

**c**CPs: 36.0% (mean) of overall prescriptions are for non-sterile compounded products; 25.7% of this number was CHT.
accounted for numerically more prescriptions of all specific CHT types (Table 2).

**Past trends and expected future growth**

Most pharmacies reported, in the survey, that their compounding business had stayed the same or had grown during the past 2 years, with 40% of ICPs and 58% of CPs citing 5% to 25% growth (Fig. 3A). More than half of the ICPs (52%) and CPs (75%) expect continued growth of their compounding business over the next 2 years, with most predicting 5% to 25% growth (Fig. 3B). Although a sizeable proportion of respondents, especially ICPs, believed that legislation may have a detrimental effect on the overall compounding market during the next 2 years (Fig. 3C), both groups seemed confident that the CHT market will remain the same or continue to grow (Fig. 3D).

**DISCUSSION**

A larger than expected proportion of US women are prescribed compounded, non-FDA–approved HT based upon extrapolations of this online market research survey of US pharmacists and data from NCPA and IBISWorld. On the basis of survey responses and industry data, an estimated 26 to 33 million CHT prescriptions are filled or dispensed annually at community and compounding pharmacies. This large number approaches that written for FDA-approved MHT, and is consistent with the revenue findings of $1 to $2 billion spent by consumers as previously found by Pinkerton and Santoro. We believe that this is the first report in the literature to estimate total annual CHT prescribing and revenue for US-independent community and compounding pharmacies.
an in Thought analysis by Symphony Health Solutions that estimated current spending on CHT is at $1.8 billion.\textsuperscript{7} The ranges of our two estimates of 26 to 33 million CHT prescriptions per year and $1.3 to $1.6 billion in annual CHT spending reflect the two separate methods of the pharmacists estimating dispensed menopausal hormones (combined estimate of CHT vs summing of individual hormonal products). The two estimates were within 20\% of one another, which was not unexpected, given that the average standard error for the survey questions that were used in the estimates was approximately 20\%. Both estimates show the large volume of CHT use.

The population of women who could benefit from FDA-approved MHT shows no sign of declining, and according to population data, may even grow.\textsuperscript{24} Ages 65 and older will be the fastest growing population segment in the United States in the next 25 years,\textsuperscript{24} and studies have shown that many women in this age group continue to experience menopausal symptoms.\textsuperscript{29-31} A study, published in 2003, of 377 women aged 50 to 69 years, reported that 26\% who had attempted to stop hormone therapy (HT) chose to resume because of troublesome postmenopausal symptoms.\textsuperscript{32} An analysis by in Thought of the current US market for MHT projected growth of revenue to $4.6 billion within the next decade, but acknowledged that the market may be affected by recent legislation that has prohibited the compounding of already available FDA-approved drugs.\textsuperscript{7} The efficacy of MHT for vasomotor symptoms is undisputed.\textsuperscript{1} For some women, CHT may be recommended over MHT because of dosing or formulation flexibility or lack of allergens (peanut oil).\textsuperscript{12,33} Some authorities suggest possible savings with CHT versus FDA-approved MHT,\textsuperscript{12,27} although others cite higher costs and lack of insurance reimbursement.\textsuperscript{17}

Pharmacists from both ICPs and CPs indicated that CHT represented an important percentage of their compounding business volume (16\% and 26\%, respectively), despite recent legislation about compounding. More than two-thirds of pharmacists from ICPs and more than three-quarters of pharmacists from CPs reported that they expected the same or greater volume of business in CHT over the next 2 years.

Many women and some healthcare providers may be unaware of the lack of FDA oversight of CHT. In the survey reported by Itikhar et al,\textsuperscript{13} more than two-thirds of 184 women (67\%) believed that CHT was safer than FDA-approved MHT. Similarly, in the consumer surveys by Pinkerton and Santoro\textsuperscript{16} cited earlier, only 14\% of respondents

---

**FIG. 3.** Survey respondents’ outlook on growth of the compounding industry, including (A) reported past growth, (B) expected future growth; and the expected impact of legislation on (C) the overall US compounding industry, considering “recent legislation (national and state)” and (D) the compounded hormone therapy market over the next 2 years, considering changes “specifically because of the law as opposed to general economic conditions.” CPs, compounding pharmacies; ICPs, independent community pharmacies; NA, not applicable. Responses to C and D were on a scale of 1 to 7 (from “significant decrease” to “significant increase”).
reported that they knew that CHT was not FDA-approved, with 76% saying “not sure” and 10% saying they believed that CHT was FDA-approved. Twenty-seven percent of women did not know whether their MHT formulation had been compounded. Sixty-seven percent of women who responded to a “10-minute” paper survey offered at compounding pharmacies agreed that “natural” hormones are safer and cause fewer side effects than “synthetic” hormones, and in a questionnaire given online or on paper to women with nonmetastatic breast cancer, 79% admitted a lack of knowledge about risk-benefit considerations of bio-identical and nonhormonal treatments for symptoms of menopause. Certain types of CHT have been touted to have the ability to prevent chronic diseases such as breast cancer and cardiovascular disease, achieve weight loss, or slow the aging process without robust clinical studies to back up these assertions. It is of concern that women may assume CHT products to be safe because no warnings are provided about their risks, and the FDA does not require CHT product regulation. Additionally, CHT products do not come with a package insert of indications and potential risks, whereas all FDA-approved estrogen products include this along with the boxed warning based on the findings from the WHI.

The American Congress of Obstetricians and Gynecologists (ACOG), the American Association of Clinical Endocrinologists (AACE), the American College of Clinical Pharmacy (ACCP), the Australian Menopause Society (AMS), the Endocrine Society, The North American Menopause Society (NAMS), the American Society for Reproductive Medicine (ASRM), and the US Preventive Services Task Force have released statements on their concerns about the lack of rigorous randomized trials on CHT, and the AACE also emphasized the potential for exaggerated claims of safety and efficacy. These professional organizations state that women should be advised to use FDA-approved products whenever possible instead of CHT regimens, given the wide range of FDA-approved combinations, dosages, and dosage forms of bioidentical HT options.

Shared decision-making about MHT should include discussion of FDA-approved therapies. Concern exists about the potential of liability if women are not educated about unique risks possible with CHT, and thus documentation should include why CHT is being recommended over FDA-approved therapies. Before considering or prescribing CHT, women should be counseled about the potential risks and unknowns possible with compounded products and lack of FDA approval and monitoring. Women should understand that compounding pharmacies can be licensed through PCAB, which allows identification of pharmacies that have passed a national certification process. Ideally, pharmacists would thoroughly document origin, purity, dose, and sterility of compounded product(s).

Limitations of this study include the self-selected participation by pharmacists in this survey; thus the findings may be limited by sampling bias due to the survey design and participants’ self-report. Consequently, the participants may not be representative of all ICPs and CPs in the United States. Demographic data on the pharmacists were not collected and thus no comments can be made about the age, race, sex, and so on of the participants. However, the geographical distribution of the pharmacists surveyed (Appendix C, Supplemental Digital Content 3, http://links.lww.com/MENO/A143) shows that pharmacists across the nation responded and a wide geographic range was achieved. Another limitation was that we could not correct for the number of pharmacists who responded per pharmacy due to the confidential nature of the survey. Thus, although multiple pharmacists from a single pharmacy could have responded to the survey, reassurance is provided that the results were not affected, given the large number of pharmacists participating (see Fig. 1), their widespread geographic distribution (see Appendix C, Supplemental Digital Content 3, http://links.lww.com/MENO/A143), and the small average number of pharmacists per pharmacy (see Appendix B, Supplemental Digital Content 2, http://links.lww.com/MENO/A142). Despite the limitations associated with response rates in surveys, conducting a survey was the only current option available to estimate the size of the compounding market, given that compounding prescriptions and revenue are not tracked in a systematic manner. The response rate in this study was relatively robust at 24% of the eligible 12,250 pharmacists, compared with the 9% to 10% figure cited recently for online and telephone surveys.

Estimated calculations using national data have inherent risks of over or underestimation. However, the most recent, relevant published industry data available (NCPA27 and IBIS-World) were used to perform the reported extrapolations. In addition, the pharmacists were asked questions about compounding MHT in two different ways (see Appendix A, Supplemental Digital Content 1, http://links.lww.com/MENO/A141) to provide internal consistency for the numbers found in the survey.

CONCLUSIONS

This analysis and extrapolation of survey data provide new and potentially valuable information on the extent of compounding of postmenopausal hormone preparations obtained from online survey data among US ICPs and CPs. On the basis of extrapolations of the survey data using national published data (see Fig. 2), CHT accounts for an estimated 26 to 33 million prescriptions annually, reaching potentially $1.3 to $1.6 billion in revenues, and pharmacists expect continued growth in the CHT market over the next 2 years. Our results are consistent with those of a survey of consumers recently published by Pinkerton and Santoro, with 21 to 39 million CHT prescriptions and a revenue of $1 to $2 billion annually reported. Large numbers of women are exposed to CHT with prescription volume approaching that of FDA-approved MHT; growth is expected in the CHT market by compounding and independent pharmacists; and CHT carries unique risks due to lack of FDA approval or monitoring.
women who visit them about the differences between FDA-approved and less regulated CHT formulations, and the availability of FDA-approved and monitored therapies. This study also demonstrates the need for more research on the efficacy, safety, and consistency of non-FDA-approved CHT to better understand benefits and risks for our patients and the need for tracking non-FDA-approved menopausal hormone therapies to better understand how and why it is being used.

REFERENCES

1. North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
2. MacLennan AH, Gill TK, Broadbelt JL, Taylor AW. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009;12:122-130.
3. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120:595-603.
4. Steinkefiller AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 2012;19:616-621.
5. Stagnitti M, LeFkowitz D. Trends in hormone replacement therapy drug utilization and expenditures for adult women in the US civilian non-institutionalized population, 2001-2008. Agency Healthc Res Qual 2011;1-9.
6. Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL. Trends of postmenopausal estrogen plus progesteron prevalence in the United States between 1970 and 2010. Obstet Gynecol 2014;124:727-733.
7. Zuckerman M, Weintraub B, Martin C, Hoggatt J. The hormone replacement therapy market for the treatment of menopausal symptoms in the US. Symphony Health Solutions 2013;13:19. Available at: http://symphonyhealth.com/product/pharmaceutical-audit-suite-phaSt. Accessed February 17, 2015.
8. Buist DS, Newton KM, Migliorelli DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
9. Ness J, Aronow WS, Newkirk E, McDaniel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women’s Health Initiative trial. J Gerontol A Biol Sci Med Sci 2005;60:460-462.
10. Bio-identicals: sorting myths from facts. US Food and Drug Administration Website. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049311.htm. Accessed April 30, 2015.
11. Supreme Court of the United States. Thompson, Secretary of Health and Human Services, et al. v. Western States Medical Center et al. No. 01-344. April 29, 2002.
12. American College of Obsetricians and Gynecologists Women’s Health Care Physicians. Compounded bioidentical menopausal hormone therapy. Committee Opin 2012;1-5.
13. Ifthikar S, Shuster LT, Johnson RE, Jenkins SM, Wahner-Roedler DL. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt) 2011;20:559-565.
14. Pinkerton JV. “Bioidenitical” hormones. What you (and your patient) need to know. OBG Manage 2009;21:42-52.
15. Boothby LA, Doering PL, Kipersztok S. Bioidenitical hormone therapy: a review. Menopause 2004;11:356-367.
16. Pinkerton J, Sartorobio N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926-936.
17. AACE. American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee Position Statement on Bioidentical Hormones. Available at: https://www.aace.com/files/position-statements/aacebhsstatement071507.pdf. Accessed February 14, 2015.
18. Akmak N, Brochu L, Malik B, Bayot A. Promotion and marketing of bioidentical hormone therapy on the internet: a content analysis of websites. Menopause 2014;21:1329. Abstract S-10.
19. US Food and Drug Administration. FDA takes action against compounded menopause hormone therapy drugs. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116832.htm. Accessed February 17, 2015.
20. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on compounding nonsterile products in pharmacies. Am J Hosp Pharm 1994;51:1441-1448.
21. McDonough RP, Allen LV, Wettergreen S. The art, science, and practice of pharmacy compounding. J Am Pharm Assoc (2003) 2013;53:8-12.
22. Pharmacy Compounding Accreditation Board: For Pharmacists. Available at: http://achc.org/pcab. Accessed March 4, 2015.
23. USP Compounding Standards and Resources. Available at: http://www.usp.org/usp-healthcare-professionals/compounding. Accessed March 23, 2015.
24. US Census Bureau. Aging boomers will increase dependency ratio, census bureau projects. Available at: https://www.census.gov/newsroom/releases/archives/aging_population/cb10-72.html. Accessed February 17, 2015.
25. National Community Pharmacists Association. 2013 NCPA Digest sponsored by Cardinal Health. Available at: http://www.ncpanet.org/solutions/nca-digest-sponsored-by-cardinal-health. Accessed January 2015.
26. Turk S. IBISWorld Industry Report OD5706: compounding pharmacies. Available at: http://www.ibisworld.com. Accessed February 2015.
27. Barenberg BJ, Smith T, Nihira MA. Compounded estradiol cream: a cost conscious alternative. J Okla State Med Assoc 2014;107:155-156.
28. BodyLogicMD. BodyLogic FAQ. Available at: http://www.bodylogicmd.com/faq/if-i-decide-to-start-on-a-bioidentical-hormone-therapy-program-how-much-will-it-cost. Accessed February 17, 2015.
29. Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. BJOG 2012;119:40-50.
30. Pollici MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507-1513.
31. Jarvstrat L, Spetz Holm AC, Lindh-Astrand L, Hoffmann MJ, Fredrikson GM, Hammar ML. Use of hormone therapy in Swedish women aged 80 years or older. Menopause 2015;22:275-278.
32. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239.
33. Souter PD. Physicians and compounding pharmacies: liability issues related to the prescribing and investing in such ventures. Physician Organizations Newsletter 2013;16:6-8. Available at: http://www.healthlawyers.org/Authors/PracticeGroups/PO/Documents/Newsletters/Physicians_Dec13.pdf. Accessed August 11, 2014.
34. Adams C, Cannell S. Women’s beliefs about “natural” hormones and natural hormone replacement therapy. Menopause 2001;8:433-440.
35. Sayakhot P, Vincent A, Teede H. Breast cancer and menopause: perceptions of diagnosis, menopause therapies and health behaviors. Climacteric 2012;15:59-67.
36. Boothby LA, Doering PL. Bioidentical hormone therapy: a panacea that lacks supportive evidence. Curr Opin Obstet Gynecol 2008;20:400-407.
37. US Department of Health and Human Services. Guidance: compounding of human drug products under section 503A of the Federal Food, Drug and Cosmetic Act. July 2014. Available at: http://www.fda.gov/Draft Guidance/ComplianceInformation/Guidances/defaul.htm. Accessed February 2015.
38. Moyer VA, US Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions. US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
39. McBane SE, Borgelt LM, Barnes KN, Westberg SM, Lodise NM, Stassinos M. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women’s Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:410-423.
40. Australian Menopause Society. Bioidentical hormones for menopausal symptoms information sheet. Available at: http://www.menopause.org.au/images/stories/infoshets/docs/AMS_Bioidentical_Hormones_for_Menopausal_Symptoms.pdf. Accessed September 26, 2014.

Copyright @ 2016 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
41. The Endocrine Society. Bioidentical hormones: Position statement. October 2006.
42. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. *Drugs* 2012;72:2043-2050.
43. Choi B, Pak A. A catalog of biases in questionnaires. Preventing Chronic Disease. Available at: http://www.cdc.gov/pcd/issues/2005/jan/04_0050.htm. Accessed February 15, 2015.
44. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. *Int J Qual Health Care* 1999;11:187-192.
45. American Association for Public Opinion Research Standards Committee. AAPOR report on online panels. Available at: https://www.aapor.org/AAPORKenetics/AAPOR_Main/media/MainSiteFiles/AAPOROnlinePanelsTFReportFinalRevised1.pdf. Accessed February 15, 2015.
46. The Pew Research Center. Assessing the representativeness of public opinion surveys. Available at: http://www.people-press.org/files/legacy-pdf/Assessing%20the%20Representativeness%20of%20Public%20Opinion%20Surveys.pdf. Accessed November 4, 2014.
47. DiSogra C, Callegaro M. Computing response rates for probability-based web sites. *JSM* 2009;5309-5320.